Track Oncternal Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Oncternal Therapeutics, Inc. ONCT · Stock Open Oncternal Therapeutics, Inc. in new tab

0.5266 USD
Loading chart...

DCF valuation

Model fair value for Oncternal Therapeutics, Inc. (ONCT)
Result
Sign in to run the valuation for ONCT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Oncternal Therapeutics, Inc. Logo Oncternal Therapeutics, Inc. Analysis (ONCT)

United States Health Care Official Website Stock

Is Oncternal Therapeutics, Inc. a good investment? Oncternal Therapeutics, Inc. (ONCT) is currently trading at 0.5266 USD.

Investor FAQ

Does Oncternal Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Oncternal Therapeutics, Inc.?

Oncternal Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Exchange Ticker
NMS (United States) ONCT
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Dec. 6, 2016 1:10
Jan. 8, 2024 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion